News

Trek Therapeutics in the News

May, 2017 – Article: “Dancing to the Same Tune?” in Trends in Patient Centricity

 

April 20, 2017 – Eyeforpharma Interview with Ann Kwong, Part I

 

April 20, 2017 – Eyeforpharma Interview with Ann Kwong, Part II

 

Mar 2, 2017 – Article: “A Marriage Made in Heaven” at eyeforpharma.com

 

Dec 14, 2016 – STAT Interview with Trek Therapeutics CEO Ann Kwong
Nov 3, 2016 – Washington Post feature article

Press Releases

Feb 13, 2017 -Trek Therapeutics Announces Oral Presentation of Faldaprevir, TD-6450 and Ribavirin Ph2a Trial Results at the Asian Pacific Association for the Study of the Liver on February 18, 2017 in Shanghai
[PDF]
Sep 15, 2016 – Interim Results from Trek Therapeutics’ Phase 2 Study Show Triple Combination Therapy Achieves 100% SVR4 in Genotype 4 HCV Patients
[PDF]
Aug 17, 2016 – Medivir Licenses Rights to MIV-802 to Trek Therapeutics

[PDF]

Jul 26, 2016 -Trek Therapeutics Acquires Two Antiviral Inhibitors From Vertex Pharmaceuticals
[PDF]
Jun 21, 2016 -Trek Therapeutics Initiates Phase 2a Study of Faldaprevir and TD-6450, With and Without Ribavirin, in Patients with HCV GT 1b
[PDF]
Oct 27, 2015 – Theravance Biopharma and Trek Therapeutics Announce Initiation of Phase 2a Trial of TD-6450, an NS5A Inhibitor to Treat Hepatitis C
[PDF]

Presentations/Publications by Trek-affiliated Members

HEP DART 2015, December 6-10, Wailea, USA
Price and Affordability of Hepatitis C Drugs: How Did We Get Into This Mess? (Cami Graham, MD, MPH)
Eliminating HCV: Why Highly Effective Drugs Are Not Enough (Ann Kwong, PhD)